SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Dorph C, Englund P, Nennesmo I, Lundberg IE. Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis. Ann Rheum Dis 2006; 65: 156571.
  • 2
    Englund P, Lindroos E, Nennesmo I, Klareskog L, Lundberg IE. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am J Pathol 2001; 159: 126373.
  • 3
    Li CK, Varsani H, Holton JL, Gao B, Woo P, Wedderburn LR. MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 2004; 31: 6059.
  • 4
    Mastaglia FL, Phillips BA, Zilko P. Treatment of inflammatory myopathies. Muscle Nerve 1997; 20: 65164.
  • 5
    Zilko PJ, Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: optimum immunosuppressive treatment. BioDrugs 1997; 7: 26272.
  • 6
    Lundberg I, Kratz AK, Alexanderson H, Patarroyo M. Decreased expression of interleukin-1α, interleukin-1β, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2000; 43: 33648.
  • 7
    Nyberg P, Wikman AL, Nennesmo I, Lundberg I. Increased expression of interleukin 1α and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol 2000; 27: 9408.
  • 8
    Sabina RL, Swain JL, Olanow CW, Bradley WG, Fishbein WN, DiMauro S, et al. Myoadenylate deaminase deficiency: functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J Clin Invest 1984; 73: 72030.
  • 9
    Fishbein WN. Myoadenylate deaminase deficiency: inherited and acquired forms. Biochem Med 1985; 33: 15869.
  • 10
    Sabina RL, Fishbein WN, Pezeshkpour G, Clarke PR, Holmes EW. Molecular analysis of the myoadenylate deaminase deficiencies. Neurology 1992; 42: 1709.
  • 11
    Bausch-Jurken MT, Mahnke-Zizelman DK, Morisaki T, Sabina RL. Molecular cloning of AMP deaminase isoform L: sequence and bacterial expression of human AMPD2 cDNA. J Biol Chem 1992; 267: 2240713.
  • 12
    Mahnke-Zizelman DK, Eddy R, Shows TB, Sabina RL. Characterization of the human AMPD3 gene reveals that 5′ exon usage is subject to transcriptional control by three tandem promoters and alternative splicing. Biochim Biophys Acta 1996; 1306: 7592.
  • 13
    Mahnke-Zizelman DK, Sabina RL. Cloning of human AMP deaminase isoform E cDNAs: evidence for a third AMPD gene exhibiting alternatively spliced 5′-exons. J Biol Chem 1992; 267: 2086677.
  • 14
    Van Kuppevelt TH, Veerkamp JH, Fishbein WN, Ogasawara N, Sabina RL. Immunolocalization of AMP-deaminase isozymes in human skeletal muscle and cultured muscle cells: concentration of isoform M at the neuromuscular junction. J Histochem Cytochem 1994; 42: 8618.
  • 15
    Fischer H, Esbjornsson M, Sabina RL, Stromberg A, Peyrard-Janvid M, Norman B. AMP deaminase deficiency is associated with lower sprint cycling performance in healthy subjects. J Appl Physiol 2007; 103: 31522.
  • 16
    Norman B, Nygren AT, Nowak J, Sabina RL. The effect of AMPD1 genotype on blood flow response to sprint exercise. Eur J Appl Physiol 2008; 103: 17380.
  • 17
    Sabina RL, Sulaiman AR, Wortmann RL. Molecular analysis of acquired myoadenylate deaminase deficiency in polymyositis (idiopathic inflammatory myopathy). Adv Exp Med Biol 1991; 309B: 2035.
  • 18
    Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A 2000; 97: 920914.
  • 19
    Li CK, Knopp P, Moncrieffe H, Singh B, Shah S, Nagaraju K, et al. Overexpression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis. Am J Pathol 2009; 175: 103040.
  • 20
    Salomonsson S, Grundtman C, Zhang SJ, Lanner JT, Li C, Katz A, et al. Upregulation of MHC class I in transgenic mice results in reduced force-generating capacity in slow-twitch muscle. Muscle Nerve 2009; 39: 67482.
  • 21
    Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005; 52: 182435.
  • 22
    Raben N, Nagaraju K, Lee E, Plotz P. Modulation of disease severity in mice with targeted disruption of the acid α-glucosidase gene. Neuromuscul Disord 2000; 10: 28391.
  • 23
    Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, et al. Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 2009; 39: 591602.
  • 24
    Rayavarapu S, Van der Meulen JH, Gordish-Dressman H, Hoffman EP, Nagaraju K, Knoblach SM. Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype. PLoS One 2010; 5: e12981.
  • 25
    Sims B, Mahnke-Zizelman DK, Profit AA, Prestwich GD, Sabina RL, Theibert AB. Regulation of AMP deaminase by phosphoinositides. J Biol Chem 1999; 274: 257017.
  • 26
    Di Giovanni S, Knoblach SM, Brandoli C, Aden SA, Hoffman EP, Faden AI. Gene profiling in spinal cord injury shows role of cell cycle in neuronal death. Ann Neurol 2003; 53: 45468.
  • 27
    Casciola-Rosen L, Nagaraju K. Immunoblotting of single cell types isolated from frozen sections by laser microdissection. Methods Enzymol 2002; 356: 709.
  • 28
    Lunemann JD, Schmidt J, Schmid D, Barthel K, Wrede A, Dalakas MC, et al. β-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol 2007; 61: 47683.
  • 29
    Dastmalchi M, Alexanderson H, Loell I, Stahlberg M, Borg K, Lundberg IE, et al. Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis Rheum 2007; 57: 130310.
  • 30
    Morisaki H, Morisaki T, Newby LK, Holmes EW. Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect. J Clin Invest 1993; 91: 227580.
  • 31
    Morisaki H, Higuchi I, Abe M, Osame M, Morisaki T. First missense mutations (R388W and R425H) of AMPD1 accompanied with myopathy found in a Japanese patient. Hum Mutat 2000; 16: 46772.
  • 32
    Alger HM, Raben N, Pistilli E, Francia DL, Rawat R, Getnet D, et al. The role of TRAIL in mediating autophagy in myositis skeletal muscle: a potential nonimmune mechanism of muscle damage. Arthritis Rheum 2011; 63: 344857.
  • 33
    Parker KC, Kong SW, Walsh RJ, Salajegheh M, Moghadaszadeh B, Amato AA, et al. Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis. Muscle Nerve 2009; 39: 73953.